Regeneron Pharmaceuticals, Inc. is the assignee on US20260199503A1, "GLP1R Agonist-Tethered GDF8 Antibody Conjugates and Uses Thereof," published 2026-07-16 as a kind-code A1 document — a pending application, not a granted patent. What it claims is a single molecule built out of two well-known pieces of biology welded together by linker chemistry, and what makes it worth a deals reporter's attention is less the biology than the manufacturing claims filed alongside it.

Claim 1 sets the architecture. It recites a composition comprising a GLP1R agonist-tethered GDF8 antibody conjugate, or a pharmaceutically acceptable salt thereof, made of three parts: an antibody, or antigen-binding fragment, that specifically binds to and/or blocks the biological activity of Growth and Differentiation Factor-8 (GDF8, identified in the record as SEQ ID NO: 1); at least one glucagon-like peptide-1 receptor (GLP1R) agonist; and at least one linker covalently connecting the agonist to the antibody. The direction matters and is easy to get backwards. The antibody is the carrier and its target is GDF8, the protein also known as myostatin. The GLP1R agonist is the payload riding on it. The record's abstract instead describes the conjugates as comprising antibodies against GLP1R — a characterization that does not match the title or any operative claim in this document, and that reads as boilerplate carried over from an earlier filing in Regeneron's GLP1R conjugate family. The claims are the operative text. Claim 25 gives the same construct as a formula — rendered in the record as a structure figure rather than as text — where BA is the GDF8-binding antibody, P is the GLP1R agonist, L is the linker, and n, the number of payloads per antibody, is claimed as ranging from about 1 to about 16. That range is a claim boundary, a fence the applicant is asking for. It is not a tested or optimized value, and the record as published offers no basis to read it as one.

The chemistry claims are the platform claims

The more revealing part of the filing is that Regeneron did not stop at claiming the molecule. Independent claims 81, 87, 101, 114 and 140 sit alongside claim 1, and several of them are directed at process rather than composition. Claim 81 claims the manufacturing route itself:

A process for manufacturing a conjugate of GLP1R agonist tethered GDF8 antibody or antigen binding fragment thereof comprising a) covalently attaching a handle comprising a first reactive moiety for Click or Diels-Alder reaction, in the presence of microbial transglutaminase; b) exposing a GLP1R agonist comprising a second reactive moiety for Click or Diels-Alder reaction, wherein the first and the second reactive moieties are complimentary to each other and form a stable conjugate; and c) isolating or purifying the conjugate of GLP1R agonist tethered GDF8 antibody or antigen binding fragment thereof.— GLP1R Agonist-Tethered GDF8 Antibody Conjugates and Uses Thereof, US20260199503A1

The misspelling of complementary in that claim is the source's own, reproduced here as published. Claim 101 narrows the same idea to a single named residue: a process for conjugating a drug, ligand, or handle site-specifically to an isolated antibody or fragment, where the site of conjugation is at Gln/Q55 of the antibody light chain and the conjugation is assisted by microbial transglutaminase (mTG). Claim 87 restates the conjugate in its most general form — an antigen-binding protein that binds and/or blocks GDF8, with a GLP1R agonist attached through a linker. Read as a set, these are process-control claims. Enzyme-directed attachment at one defined position, rather than stochastic attachment across whatever residues are available, is what separates a homogeneous conjugate with a controlled drug-to-antibody ratio from a mixture. Filing on the process, the site, and the composition in one document is a claim-layering pattern that covers the product and the route to it separately. That is a portfolio decision, and it is legible directly from the claim set.

Where it sits in the filing record

The chemistry in claim 81 is not confined to this document. US20260053938A1, "Diels-Alder Conjugation Methods," published 2026-02-26 — months before this week's drop, not alongside it — claims protein-payload conjugates made by combining transglutaminase with Diels-Alder chemistry: the same platform the hero's process claim invokes, filed as its own document with a different inventor. US20260139044A1 (2026-05-21), "Tumor-Targeted Split IL2 Receptor Agonists," applies an antibody-tethered-agonist design in an unrelated target space. US20260092123A1 (2026-04-02) covers IgG scaffolds engineered with an IgM Cμ2 domain swapped in for the hinge. Around those sit filings on the unglamorous half of a biologics operation. US20260152545A1 (2026-06-04) claims metabolically shifted cell culture for large-scale protein production. US20260118314A1 (2026-04-30) covers microchip capillary electrophoresis assays for purity and impurity identification in protein drug product. US20260183404A1 (2026-07-02) addresses fatty-acid particle formation in formulations. None of these published this week; each carries its own date above. Together they describe a company filing continuously across conjugate chemistry, production, and analytics through 2026.

The other Regeneron record in the 2026-07-16 drop is unrelated to conjugates: US20260201410A1, "Transcription Modulation in Animals Using CRISPR/Cas Systems," claiming non-human animal cells and animals carrying CRISPR/Cas synergistic activation mediator components for raising target-gene expression in vivo. Two facts about the hero are checkable and worth stating flatly. First, the inventor list runs eleven names and ends with Andrew J. Murphy and George D. Yancopoulos. That is what the record says; what it means for internal priority is not in the document, and we are not going to guess. Second, the claim set is heavily cancelled — eight blocks are marked canceled, spanning claims 2–24, 26–56, 73–80, 82–86, 88–100, 102–113, 124–139 and 141–147, against 34 populated entries in numbering that reaches 147. Scope here is actively under negotiation with the examiner. The claims as published are not the claims as granted, if they are granted at all. The application is classified under CPC codes including A61K 47/6845, A61K 47/6811 and A61K 47/6889 — the antibody-drug-conjugate and carrier-linked-payload family — along with C07K 16/22 for antibodies against growth factors and A61P 3/04. The classification center of gravity is conjugate chemistry, which is also where the claims spend their effort. Whether any of this becomes a molecule, the record does not say, and neither will we: it names no program, no asset, no partner, and no product.